WO2002036092A2 - Melange pour traiter la peau - Google Patents

Melange pour traiter la peau Download PDF

Info

Publication number
WO2002036092A2
WO2002036092A2 PCT/EP2001/012782 EP0112782W WO0236092A2 WO 2002036092 A2 WO2002036092 A2 WO 2002036092A2 EP 0112782 W EP0112782 W EP 0112782W WO 0236092 A2 WO0236092 A2 WO 0236092A2
Authority
WO
WIPO (PCT)
Prior art keywords
mixture according
skin
oil
hydrocarbons
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/012782
Other languages
German (de)
English (en)
Other versions
WO2002036092A3 (fr
Inventor
Michael Petry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP01992562A priority Critical patent/EP1333802A2/fr
Priority to AU2002216996A priority patent/AU2002216996A1/en
Publication of WO2002036092A2 publication Critical patent/WO2002036092A2/fr
Publication of WO2002036092A3 publication Critical patent/WO2002036092A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the invention relates to a mixture for treating the skin.
  • human skin performs numerous vital functions, for example by protecting it from cold, heat, radiation, the effects of chemical substances and pathogens. If the skin can no longer adequately fulfill this barrier function, this can result in local irritation and disruption or even physical complaints.
  • a disorder of the skin which has become increasingly important in recent years, is the clinical picture of atopic dermatitis, which manifests itself in local or extensive, sometimes chronic eczema (also atopic eczema).
  • the proportion of the total population affected by neurodermatitis is now estimated to be 2.5%, with the percentage among school-age children even being around 10%.
  • atopic dermatitis Although the causes of atopic dermatitis have not yet been conclusively clarified, and environmental factors such as genetic disposition are being discussed, the skin disorders accompanying the atopic dermatitis are known. Inadequate skin oiling in combination with a reduced water and urea content is of particular importance. Other symptoms, such as decreased skin circulation Further typical phenomena include an increased sensitivity to external stimuli such as dust or soap. The symptoms associated with atopic dermatitis are often increased by bacterial or viral secondary infections of the affected areas of the skin.
  • the skin care products used for basic care are mainly lipophilic creams, ie water-in-oil or oil-in-water emulsions, which consist to a large extent of water and water-soluble components.
  • Such a care product is known from EP 0 103 911 A1. It consists of 9 to 89% petroleum jelly, to which an emulsifier is added up to a maximum proportion of 10%. In addition, it contains up to a maximum of 25% of a pharmaceutically active substance. The rest is made up of water, which can take up to 90%.
  • the disperse phase within the emulsion which is formed by the petroleum jelly component, serves to transport the pharmaceutically active substances into the skin.
  • water-containing emulsions are a preferred breeding ground for microorganisms.
  • water-based care products usually contain preservatives and anti- crobial substances. However, these in turn can lead to allergies or unwanted skin irritation.
  • NZ 28 60 73 A It is therefore the aim of NZ 28 60 73 A to provide a main care product for moisturizing and maintaining the natural moisture of the skin, which does not contain any antimicrobial substances.
  • the skin care product known from this publication contains the following substances:
  • the polybutenes are polybutene polymers with a molecular weight between 200 and 2000 Da, preferably with 200 to 500 Da. This corresponds to a carbon chain length from C 14 to C 140 to about C 14 to C 35 .
  • the natural fatty acids have their origin preferably in vegetable or animal oils, stearic acid, oleic acid and palmitic acid from the sebaceous glands of the cod being said to be particularly advantageous.
  • the polybutenes are assigned the function of placing a protective layer on the skin in the sense of a barrier.
  • This protective layer is said to be permeable to oxygen in order to allow the skin to heal, the O 2 permeability being guaranteed by the fatty acids.
  • an antioxidant for example ⁇ -tocopherol
  • the known skin care products have so far failed to relieve the majority of patients suffering from neurodermatitis from their symptoms.
  • the object of the invention is to provide a skin care product which is particularly effective against acute and chronic atopic eczema, especially neurodermatitis.
  • the object is achieved by a mixture according to claim 1.
  • Advantageous further developments are the subject of the corresponding subclaims.
  • the invention is based on the idea of providing a mixture of oils and hydrocarbons, the oils being able to dry and the hydrocarbons having a C chain length which also allows them to penetrate into the deeper layers of the skin. Due to the dryness of the oils, i.e. by the oxidation of the mono- or polyunsaturated fatty acids contained in the oils in high proportions, a film or a layer is formed on the skin. At the same time, the hydrocarbons penetrate the skin. These processes cause the skin to dry out in two ways, namely on the one hand by preventing the absorption of water by the non-permeable layer of hardened fatty acids and on the other hand by displacing the water in the deeper skin layers.
  • unsaturated fatty acids and hydrocarbons in particular are not suitable - even counterproductive - for the treatment of serious skin problems, especially neurodermatitis.
  • the surprisingly therapeutically effective mixture according to the invention essentially consists of drying oils which, through their curing, achieve the above-mentioned effect of film formation on the skin, and the hydrocarbons penetrating into the lower layers of the skin.
  • the essentially drying oils are represented with a share of up to 40%, while the hydrocarbons make up a share of up to 50%.
  • Drying oils or essentially drying oils have a high proportion of polyunsaturated fatty acids.
  • drying oil is also used to refer to oils which do not consist exclusively of polyunsaturated fatty acids, but which have a considerable proportion. These fatty acids preferably have a carbon chain length of C 15 to C 20 . It can also be semi-drying oils, which also show the properties of film formation or hardening.
  • a particularly advantageous representative of the drying oils is linseed oil (also oleum lini) with a predominantly unsaturated fatty acids, namely 49 to 53% linolenic acid, 15 to 16% linoleic acid and 21 to 23% oleic acid.
  • the linoleic acid is also found in high proportions in poppy seed oil (approx. 62%), sunflower oil (approx. 52%), cottonseed oil (45%) or olive oil (10 to 15%). Sesame or hemp oil as well as corn and soybean oil are also suitable. These vegetable oils are also advantageously to be used in the mixture according to the invention.
  • hydrocarbons used according to the invention are suitable for penetrating the skin. This suitability is demonstrated, for example, by simple hydrocarbons with a chain length of C 5 to C. If hydrocarbons with a longer chain length, for example up to C 20 , are also used, a certain proportion of an organic solvent can advantageously be added to the mixture. This can serve to dilute the otherwise viscous to solid hydrocarbons. These can also penetrate the skin.
  • hydrocarbons can be used in mixtures of different qualities, and can also be present as cyclic compounds.
  • Another advantage of the mixture according to the invention is to create a barrier on the skin against the ingress of oxygen.
  • This barrier is built up both by the fatty acids hardening on the skin surface and by the deeper penetrating hydrocarbons. Passing 0 2 is thus made difficult or impossible. This in turn deprives a large number of microorganisms of their death, some of which can be responsible for secondary infections on the irritated skin areas.
  • the antimicrobial effect of the mixture according to the invention can be further increased by adding pharmacologically active substances, such as, for example, antiseptic agents.
  • pharmacologically active substances such as, for example, antiseptic agents.
  • iodine or chamomile for example, in a relative proportion of up to 2% is advantageous. These can be transported from the hydrocarbons into the deeper layers of the skin.
  • additives are added to the mixture to improve the cosmetic or pharmaceutical effectiveness, the application to the skin and to stabilize the mixture.
  • additives can be, for example, thickeners for regulating the viscosity, light protection filters for protecting skin-sensitive constituents and the skin, fragrances and vitamins including provitamins.
  • Carrier systems such as niosomes or nanoparts can also be used, which represent the reverse principle of liposomes.
  • the mixture can have a liquid to oily or even waxy consistency, so that it is to be applied to the skin in the form of an ointment.
  • Processing in the form of mixing, extracting, filtering or cleaning or the like can be used to provide a mixture according to the invention, including pharmacologically or cosmetically active additives and the additives mentioned by way of example. to be required.
  • a mixture formulated or made up with one or more additives and having the suitability and nature of a medicinal product, is defined as a "pharmaceutical formulation" for the following purposes.
  • Another particular advantage of the mixture according to the invention is that its formulation and preparation does not require any complex preparation steps. In this way, the parts can easily be mixed with one another without further pre- and post-treatment.
  • the subsequent treatment with the mixture according to the invention included daily rubbing in of the foot. No further measures, such as bandages or disinfection of the affected skin areas, were carried out.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne un mélange pour traiter la peau, notamment pour traiter la neurodermite, qui contient des huiles déshydratantes et des hydrocarbures pénétrant la peau.
PCT/EP2001/012782 2000-11-04 2001-11-05 Melange pour traiter la peau Ceased WO2002036092A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01992562A EP1333802A2 (fr) 2000-11-04 2001-11-05 Melange pour traiter la peau
AU2002216996A AU2002216996A1 (en) 2000-11-04 2001-11-05 Mixture for treating skin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2000154702 DE10054702A1 (de) 2000-11-04 2000-11-04 Gemisch zur Behandlung der Haut
DE10054702.8 2000-11-04

Publications (2)

Publication Number Publication Date
WO2002036092A2 true WO2002036092A2 (fr) 2002-05-10
WO2002036092A3 WO2002036092A3 (fr) 2002-07-25

Family

ID=7662142

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/012782 Ceased WO2002036092A2 (fr) 2000-11-04 2001-11-05 Melange pour traiter la peau

Country Status (4)

Country Link
EP (1) EP1333802A2 (fr)
AU (1) AU2002216996A1 (fr)
DE (1) DE10054702A1 (fr)
WO (1) WO2002036092A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10352371A1 (de) * 2003-11-10 2005-06-09 Beiersdorf Ag Verwendung von hydrierten Sojaglyceriden in kosmetischen Zubereitungen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL266499A (fr) * 1960-07-08
GB1018454A (en) * 1962-10-18 1966-01-26 Smith Kline French Lab Improvements in or relating to antibacterial and antifungal compositions
GB2079599B (en) * 1980-07-12 1984-03-14 Torfa Akademii Nauk Medical preparations comprising peat extract
FR2745719B1 (fr) * 1996-03-11 1998-04-17 Heitz Jean Composition pour le traitement d'affections cutanees
DE19615293A1 (de) * 1996-04-18 1997-10-23 Johann Dibart Propolis-Hautproblemsalbe - Propolis-Schmerzsalbe

Also Published As

Publication number Publication date
DE10054702A1 (de) 2002-05-16
AU2002216996A1 (en) 2002-05-15
EP1333802A2 (fr) 2003-08-13
WO2002036092A3 (fr) 2002-07-25

Similar Documents

Publication Publication Date Title
EP2201942A1 (fr) Composition dotée d'huile de chanvre pour le traitement de maladies topiques
EP2001433A1 (fr) Composition pour application topique
DE3411225C2 (fr)
DE602004004880T2 (de) Hautpflegeprodukt mit tallöl-fettsäuren und pflanzenölen für trockene und schuppende haut und behandlung von psoriasis, dermatitis und ekzemen
WO2022017816A1 (fr) Agent désinfectant, toléré par la peau, nourrissant et relipidant, destiné à être appliqué sur la peau
WO1989000853A1 (fr) Agent contenant de l'acide salicylique pour le traitement de dermatoses squameuses
DE60222583T2 (de) Pharmazeutische zusammensetzung zur lokalen behandlung von hauterkrankungen und hautwunden
EP1333802A2 (fr) Melange pour traiter la peau
DE202022001251U1 (de) Pharmazeutisches Hautpflegemittel
DE68918280T2 (de) Kosmetische zusammensetzung auf der basis von chromo-carboxylaten.
DE69005113T2 (de) Verwendung von peroxidlipiden zur herstellung eines arzneimittels zur behandlung von kreislaufinsuffizienz bei lokaler applikation.
DE69116216T2 (de) Verwendung von Squalene, Squalane oder deren Mischungen zur Herstellung einer abkühlenden Zusammensetzung zur örtlichen Behandlung von Verbrennungen
DE102022128474A1 (de) Zusammensetzung umfassend Copaibaextrakt und Magnesiumsalz insbesondere zur Verbesserung des körperlichen Wohlbefindens bei Menstruationsbeschwerden oder bei allgemeinen Verspannungszuständen
EP0455631B1 (fr) Preparation contenant de l'acide salicylique pour traiter des affections dermiques desquamantes
DE102017002125A1 (de) Kosmetische Zusammensetzung
AU2021103390A4 (en) A Skincare Oil
DE102023100052B4 (de) Stoffgemisch zur Anwendung bei der topischen Behandlung eines onkologischen Hand-Fuß-Syndroms, und Verfahren zur Herstellung des Stoffgemischs
DE102019006848A1 (de) Creme zur äußeren Anwendung auf der Haut im Brust-, Bauch-, Rücken- und Unterleibsbereich zur Linderung von Menstruationsbeschwerden
DE102018115270B4 (de) Zubereitung als Gel und Pflaster zur topischen Behandlung von Haut- und/oder Nagelerkrankungen
DE60001278T2 (de) Behandlungsbalsam, insbesondere für oberflächliche verbrennungen und irritiere nde rötungen
DE4110134A1 (de) Mittel zur behandlung und pflege der haut
DE19943553C2 (de) Zusammensetzung, insbesondere Pflegebalsam
DE102004034747B4 (de) Salbenzubereitung geeignet bei neurodermitischen Hauterkrankungen
DE29822501U1 (de) Kosmetisches Gesundheitspflegemittel
DE202016000224U1 (de) Wasser-in-Öl-Emulsion

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001992562

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001992562

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001992562

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP